FDA Removes Tracking Of Operator Errors From Process Validation Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA and Pfizer successfully lobbied to have the recommendation taken out of the final guidance, calling it "too prescriptive."
You may also be interested in...
FDA's Process Validation Guidance Stresses Use of Statistical Controls
FDA's process validation guidance puts a new emphasis on statistical controls. Like it or not, the guidance offers new flexibility. Also, it expands the focus of process validation from commercial scale-up to a lifecycle approach that includes process design studies as well as continuous verification during commercial manufacturing activities.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.